Shares of Xenetic Biosciences Inc (NASDAQ:XBIO) have received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a 1-year consensus price target of $10.00 for the company, according to Zacks. Zacks has also assigned Xenetic Biosciences an industry rank of 106 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research lowered Xenetic Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st.

Xenetic Biosciences (NASDAQ:XBIO) traded down $0.07 during midday trading on Wednesday, reaching $2.12. The company’s stock had a trading volume of 5,400 shares, compared to its average volume of 16,836. Xenetic Biosciences has a one year low of $1.75 and a one year high of $5.90.

Xenetic Biosciences (NASDAQ:XBIO) last posted its earnings results on Wednesday, November 15th. The company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.03). The business had revenue of $0.09 million during the quarter. equities research analysts anticipate that Xenetic Biosciences will post -0.89 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/12/06/zacks-xenetic-biosciences-inc-xbio-given-consensus-recommendation-of-strong-buy-by-analysts.html.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.

Get a free copy of the Zacks research report on Xenetic Biosciences (XBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Xenetic Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.